FMP
Marker Therapeutics, Inc.
MRKR
NASDAQ
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
2.24 USD
-0.225 (-10.07%)
Dr. Juan F. Vera M.D.
Healthcare
Biotechnology
NASDAQ
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
0001094038
US57055L2060
57055L107
3200 Southwest Freeway
713 400 6400
US
8
Jul 16, 2002
Ms. Mary Newman Ph.D.
Head of Regulatory Affairs
0
1959
Ms. Elizabeth Donnelly
Director of Administration
0
N/A
Dr. Maria-Bernadette Madel
Director of Corporate Operations & Exter...
0
1990
Dr. Robert Z. Florkiewicz Sr.
Senior Director of Molecular Biology & V...
0
N/A
Dr. Monic Stuart M.D.
Chief Medical Officer
0
N/A
Patricia Allison
Head of Clinical Operations
0
N/A
Dr. Juan F. Vera M.D.
Co-Founder, Chief Executive Officer, Pre...
399.25k
1980
Mr. Edmund Cheung
Vice President of Human Resources
0
N/A
As of December 31, 2024, the total employee count stands at 8, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.